Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model

Abstract

Antisense oligonucleotides (ASOs) hold promise for therapeutic splice switching correction for genetic diseases, in particular for Duchenne muscular dystrophy (DMD), for which ASO-exon skipping represents one of the most advanced therapeutic strategies. We have previously reported the therapeutic potential of tricyclo-DNA (tcDNA) in mouse models of DMD, highlighting the unique pharmaceutical properties and unprecedented uptake in many tissues after systemic delivery, including the heart and central nervous system. TcDNA-ASOs demonstrate an encouraging safety profile and no particular class-related toxicity, however, when administered in high doses for several months, mild renal toxicity is observed secondary to predictable phosphorothioate (PS)-ASO accumulation in kidneys. In this study, we investigate the influence of the relative content of PS linkages in tcDNA-ASOs on exon skipping efficacy. Mdx mice were injected intravenously once weekly for 4 weeks with tcDNA carrying various amounts of PS linkages (0%, 25%, 33%, 50%, 67%, 83%, and 100%). The results indicate that levels of exon-23 skipping and dystrophin rescue increase with the number of PS linkages in most skeletal muscles except in the heart. As expected, plasma coagulation times are shortened with decreasing PS content, and tcDNA-protein binding in serum directly correlates with the number of PS linkages on the tcDNA backbone. Altogether, these data contribute in establishing the appropriate sulfur content within the tcDNA backbone for maximal efficacy and minimal toxicity of the oligonucleotide.

Get full access to this article

View all access options for this article.

References

Aupy

, Echevarría

, Relizani

and Goyenvalle.

(2017). The use of tricyclo-DNA oligomers for the treatment of genetic disorders. Biomedicines, 6:2.

Aartsma-Rus

, Straub

, Hemmings

, Haas

, Schlosser-Weber

, Stoyanova-Beninska

, Mercuri

, Muntoni

, Sepodes

, et al. (2017). Development of exon skipping therapies for duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. Nucleic Acid Ther, 27:251–259.

Crone

and Mah.

(2018). Current and emerging therapies for duchenne muscular dystrophy. Curr Treat Options Neurol, 20:31.

Echevarría

, Aupy

and Goyenvalle

. (2018). Exon-skipping advances for Duchenne muscular dystrophy. Hum Mol Genet, 27:R163–R172.

Wickstrom

. (1986). Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods, 13:97–102.

Eckstein

. (2014). Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther, 24:374–387.

Benimetskaya

, Tonkinson

, Koziolkiewicz

, Karwowski

, Guga

, Zeltser

, Stec

and Stein

. (1995). Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. Nucleic Acids Res, 23:4239–4245.

Matsukura

, Shinozuka

, Zon

, Mitsuya

, Reitz

, Cohen

and Broder

. (1987). Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A, 84:7706–7710.

Bennett

and Swayze

. (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol, 50:259–293.

10.

Iannitti

, Morales-Medina

and Palmieri

. (2014). Phosphorothioate oligonucleotides: effectiveness and toxicity. Curr Drug Targets, 15:663–673.

11.

Senn

, Burel

and Henry

. (2005). Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88. J Pharmacol Exp Ther, 314:972–979.

12.

Henry

, Beattie

, Yeh

, Chappel

, Giclas

, Mortari

, Jagels

, Kornbrust

and Levin

. (2002). Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol, 2:1657–1666.

13.

Sheehan

and Phan

. (2001). Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry, 40:4980–4989.

14.

Crooke

. (2007) Antisense Drug Technology: Principles, Strategies, and Applications, 2nd Ed. CRC Press, Boca Raton.

15.

Crooke

, Baker

, Kwoh

, Cheng

, Schulz

, Xia

, Salgado

, Bui

, Hart

, et al. (2016). Integrated safety assessment of 2'-O-Methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers. Mol Ther J Am Soc Gene Ther, 24:1771–1782.

16.

Goyenvalle

, Griffith

, Babbs

, Andaloussi

, Ezzat

, Avril

, Dugovic

, Chaussenot

, Ferry

, et al. (2015). Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat Med, 21:270–275.

17.

Relizani

, Griffith

, Echevarría

, Zarrouki

, Facchinetti

, Vaillend

, Leumann

, Garcia

and Goyenvalle

. (2017). Efficacy and safety profile of tricyclo-DNA antisense oligonucleotides in duchenne muscular dystrophy mouse model. Mol Ther Nucleic Acids, 8:144–157.

18.

Goyenvalle

, Leumann

and Garcia

. (2016). Therapeutic potential of tricyclo-DNA antisense oligonucleotides. J Neuromuscul Dis, 3:157–167.

19.

Renneberg

, Bouliong

, Reber

, Schumperli

and Leumann

. (2002). Antisense properties of tricyclo-DNA. Nucleic Acids Res, 30:2751–2757.

20.

Tyagi

and Kramer

. (1996). Molecular beacons: probes that fluoresce upon hybridization. Nat Biotechnol, 14:303–308.

21.

Sicinski

, Geng

, Ryder-Cook

, Barnard

, Darlison

and Barnard

. (1989). The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science, 244:1578–1580.

22.

Geary

, Norris

, Yu

and Bennett

. (2015). Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev, 87:46–51.

23.

, Kim

T-W

, Hong

, Watanabe

, Gaus

and Geary

. (2007). Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos Biol Fate Chem, 35:460–468.

24.

Frazier

, Sobry

, Derr

, Adams

, Besten

, Kimpe

, Francis

, Gales

, Haworth

, et al. (2013). Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide. Toxicol Pathol, 42:923–935.

25.

Agrawal

and Kandimalla

. (2004). Role of Toll-like receptors in antisense and siRNA [corrected]. Nat Biotechnol, 22:1533–1537.

26.

Swayze

, Siwkowski

, Wancewicz

, Migawa

, Wyrzykiewicz

, Hung

, Monia

and Bennett

. (2007). Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res, 35:687–700.

27.

Eckstein

. (2000). Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?. Antisense Nucleic Acid Drug Dev, 10:117–121.

28.

Galderisi

, Di Bernardo

, Melone

, Galano

, Cascino

, Giordano

and Cipollaro

. (1999). Antisense inhibitory effect: a comparison between 3'-partial and full phosphorothioate antisense oligonucleotides. J Cell Biochem, 74:31–37.

29.

Hoke

, Draper

, Freier

, Gonzalez

, Driver

, Zounes

and Ecker

. (1991). Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Res, 19:5743–5748.

30.

Zhao

, Temsamani

, Iadarola

, Jiang

and Agrawal

. (1996). Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol, 51:173–182.

31.

Frazier

. (2015). Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective. Toxicol Pathol, 43:78–89.

32.

Henry

, Jagels

, Hugli

, Manalili

, Geary

, Giclas

and Levin

. (2014). Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum. Nucleic Acid Ther, 24:326–335.

33.

Shaw

, Rustagi

, Kandimalla

, Manning

, Jiang

and Agrawal

. (1997). Effects of synthetic oligonucleotides on human complement and coagulation. Biochem Pharmacol, 53:1123–1132.

34.

Heemskerk

, de Winter

, van Kuik

, Heuvelmans

, Sabatelli

, Rimessi

, Braghetta

, van Ommen

, de Kimpe

, Ferlini

, et al. (2010). Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther, 18:1210–1217.

35.

Verhaart

, Tanganyika-de Winter

, Karnaoukh

, Kolfschoten

, de Kimpe

, van Deutekom

and Aartsma-Rus

. (2013). Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice. Nucleic Acid Ther, 23:228–237.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.84 MB

1.46 MB

1.31 MB

0.02 MB